This report identifies the global exocrine pancreatic insufficiency market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the potential growth opportunities in the coming years, while also reviewing the market drivers, restraints, growth indicators, challenges, market dynamics, competitive landscape, and other key aspects with respect to global exocrine pancreatic insufficiency market.
Geographically North America dominated global exocrine pancreatic insufficiency market, and is projected to have fastest growth, owing to rapidly growing incidences of exocrine pancreatic insufficiency and other causative diseases such as Cystic Fibrosis (CF) and Chronic Pancreatitis (CP) in the U.S. in this region. Among all the diagnostic test, Computerized Tomography (CT) scanning has the highest market share in global exocrine pancreatic insufficiency market.
This report segments global exocrine pancreatic insufficiency market on the basis of disease management, diagnostic test, and regional market as follows:
Exocrine Pancreatic Insufficiency Market, By Disease Management: Nutritional management, Pancreatic enzyme replacement therapy (PERT), Life style modifications approach, and Phase III Drugs
Exocrine Pancreatic Insufficiency Market, By Diagnostic Test: Blood Tests, Endoscopic Ultra-sonography (EUS), Magnetic Resonance Imaging (MRI), CT Scanning, and Other
This is report has been further segmented into major regions, which includes detailed analysis of each region such as: North America, Europe, Asia-Pacific (APAC), and Rest of the World (RoW) covering all the major country level markets in each of the region
This report identifies all the major companies operating in the exocrine pancreatic insufficiency market. Some of the major companies’ profiles in detail are as follows:
Nordmark Arzneimittel GmbH & Co. KG
Janssen Pharmaceuticals, Inc.
AzurRx BioPharma, Inc.
Anthera Pharmaceuticals, Inc.
Digestive Care, Inc.
Please Note: The report is to be delivered in 1-2 working days after an order is placed.
2. Executive Summary
3. Market Landscape
3.1. Market Share Analysis
3.2. Comparative Analysis
3.3. Product Benchmarking
3.4. End User Profiling
3.5. Top 5 Financials Analysis
4. Exocrine Pancreatic Insufficiency Market– Market Forces
4.1.1. Growing incidences of diseases such as cystic fibrosis, chronic pancreatitis and diabetes
4.1.2. Rise in the number of people suffering from diabetes
4.1.3. Increasing demands of advanced therapeutics
4.2.1. The research and development having higher cost
4.2.2. Stringent government regulations for the approval of Pancreatic Enzyme Replacement Therapy (PERT) products
4.3.1. Emerging economies
4.3.2. Emergence of new chemical entities (NCEs) in various phases of clinical trials in the global market
4.5. Porter’s Five Forces Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Degree of Competition
5. Exocrine Pancreatic Insufficiency Market, By Disease Management
5.1. Nutritional management
5.2. Pancreatic enzyme replacement therapy (PERT)
5.3. Life style modifications approach
5.4. Phase III Drugs
6. Exocrine Pancreatic Insufficiency Market, By Diagnostic Test
6.1. Blood Tests
6.2. Endoscopic Ultra-sonography (EUS)
6.3. Magnetic Resonance Imaging (MRI)
6.4. CT Scanning
7. Exocrine Pancreatic Insufficiency Market, By Geography
7.1.7. Rest of Europe
7.2. Asia Pacific
7.2.4. South Korea
7.2.5. Rest of Asia-Pacific
7.3. North America
7.4. Rest of the World (RoW)
7.4.2. Rest of RoW
8. Exocrine Pancreatic Insufficiency – Market Entropy
8.2. Technological Developments
8.3. Merger & Acquisitions, and Joint Ventures
8.4. Supply- Contract
9. Company Profiles (Introduction, Financials, Key Insights, Key Strategy, Product Portfolio, SWOT Analysis)
9.1. Nordmark Arzneimittel GmbH & Co. KG
9.2. Janssen Pharmaceuticals, Inc.
9.3. AzurRx BioPharma, Inc.
9.4. Anthera Pharmaceuticals, Inc.
9.5. Digestive Care, Inc.
9.6. AbbVie, Inc.
9.7. Allergan plc
9.8. Cilian AG
9.9. Eli Lilly & Co.
9.10. Laboratories Mayoly Spindler
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"
10.3. Research Methodology
10.4. Expert Insights